Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


Home > Press > Microfluidics International Corporation Announces First Quarter 2009 Financial Results

Microfluidics International Corporation (OTCBB: MFLU) today reported unaudited financial highlights for the first quarter ended March 31, 2009.

Microfluidics International Corporation Announces First Quarter 2009 Financial Results

Newton, MA | Posted on May 12th, 2009

First Quarter Accomplishments

* Maintained revenues from the prior year's quarter despite global economic downturn
* Reduced corporate cost-structure during the quarter to 2007 levels under the direction of the new leadership team

"Microfluidics had a solid first quarter and we are pleased to report that we are beginning to see increased demand for our products and services in our core growth market—pharmaceuticals," said Michael C. Ferrara, Chief Executive Officer and President of Microfluidics. "The positive signs we saw in our first quarter revenues combined with our recent cost-containment measures have us on track to achieve our goal of obtaining positive EBITDA for the year 2009—a major milestone for the Company."

First Quarter Financial Results

Revenues for the three months ended March 31, 2009 were $3,559,000, an increase of $37,000, or 1.1%, as compared to revenues of $3,522,000 for the three months ended March 31, 2008. North American revenues increased by 64% and services revenues increased by approximately 50% in comparison to the first quarter of 2008, offsetting a 44.8% decline in foreign sales. The Company believes the decline in foreign sales is a result of pricing pressure in Asia Pacific and the effects of the global economic downturn.

Net loss, as measured under U.S. generally accepted accounting principles ("GAAP"), was $690,000, or $0.07 per diluted share, for the three months ended March 31, 2009 as compared to $445,000 net loss, or $0.04 per diluted share, for the same period in 2008.

EBITDA loss was $469,000, or $0.05 per diluted share, for the three months ended March 31, 2009 compared with a $410,000 EBITDA loss, or $0.04 per diluted share, for the same period in 2008.

Live Webcast

Microfluidics International Corporation will host a webcast on Tuesday, May 12, 2009 at 8:30 a.m. Eastern Time. Participants are invited to attend the call by visiting and clicking on the webcast link in the Investors, Events section or by dialing 800-638-4817 (within the United States) or 617-614-3943 (outside the United States). The passcode for participants is 25898820.

A replay will be available approximately two hours after the live call through May 19, 2009. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 89775077. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.


About Microfluidics International Corporation
Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics and inkjet ink industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" of our most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or otherwise.

EBITDA and Non-GAAP Measures

In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure. Management believes these measures are useful and relevant to management and investors in their analysis of the Company’s underlying business and operating performance. Management also uses this information for operational planning and decision-making purposes. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies. One specific non-GAAP measure used by the Company is “EBITDA”, which is defined as earnings before interest, taxes, depreciation and amortization. Management utilizes the line item non-GAAP operations statement for operational planning and decision-making purposes. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.


Condensed Consolidated Balance Sheets

(Unaudited - in thousands, except share and per share amounts)

                                                     March 31,      December 31,

                                                     2009           2008


Current assets:

Cash and cash equivalents                            $ 850          $ 1,895

Accounts receivable, net of allowance of $44 both
at                                                     2,536          2,181
March 31, 2009 and December 31, 2008, respectively

Inventories                                            2,737          2,723

Prepaid and other current assets                       220            320

Total current assets                                   6,343          7,119

Property and equipment, net                            1,109          1,121

Other non-current assets                               481            480

Total assets                                         $ 7,933        $ 8,720


Current liabilities:

Accounts payable                                     $ 1,084        $ 986

Accrued expenses                                       1,151          1,233

Customer advances                                      280            436

Total current liabilities                              2,515          2,655

Long-term liabilities:

Convertible debt                                       4,638          4,625

Total liabilities                                      7,153          7,280

Stockholders' equity:

Common stock; $.01 par value; 20,000,000 shares
10,607,228 and 10,592,228 shares issued;
10,371,782 and                                         106            106
10,356,782 shares outstanding as of March 31, 2009
December 31, 2008, respectively

Additional paid-in capital                             18,072         18,042

Accumulated deficit                                    (16,729 )      (16,039 )

Treasury stock, 235,446 shares, at cost, as of
March 31, 2009 and                                     (669    )      (669    )
December 31, 2008

Total stockholders' equity                             780            1,440

Total liabilities and stockholders' equity           $ 7,933        $ 8,720


Condensed Consolidated Statements of Operations

(Unaudited - in thousands, except share and per share amounts)

                                               For The Three Months Ended

                                               March 31,

                                               2009              2008

Revenues                                       $ 3,559           $ 3,522

Cost of sales                                    1,653             1,609

Gross profit                                     1,906             1,913

Operating expenses:

Research and development                         452               491

Selling                                          1,216             932

General and administrative                       804               941

Total operating expenses                         2,472             2,364

Loss from operations                             (566       )      (451       )

Interest expense                                 (126       )      (5         )

Interest income                                  2                 11

Net loss                                       $ (690       )    $ (445       )

Net loss per common share:

Basic                                          $ (0.07      )    $ (0.04      )

Diluted                                        $ (0.07      )    $ (0.04      )

Weighted average number of common and common
equivalent shares outstanding:

Basic                                            10,370,628        10,260,482

Diluted                                          10,370,628        10,260,482


U.S. GAAP to Non-GAAP Measure Reconciliations and

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

(Unaudited - in thousands, except share and per share amounts)

                                For The Three Months Ended

                                March 31,

                                2009            2008

Net loss                        $ (690       )  $ (445       )

Net interest expense (income)     125             (6         )

Depreciation and amortization     96              41

EBITDA (Non-GAAP Measure)       $ (469       )  $ (410       )

Weighted average number of

common and common equivalent

shares outstanding:

Basic:                            10,370,628      10,260,482

Diluted:                          10,370,628      10,260,482

EBITDA per common share

(Non-GAAP Measure):

Basic:                          $ (0.05      )  $ (0.04      )

Diluted:                        $ (0.05      )  $ (0.04      )

For more information, please click here

MacDougall Biomedical Communications
Sarah Cavanaugh, 781-235-3060

Microfluidics International Corporation
Peter F. Byczko, 617-969-5452
Vice President of Finance and Chief Accounting Officer

Copyright © Microfluidics International Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Pixelligent Launches New PixClear® Light Extraction Materials for OLED Lighting August 4th, 2015

The annual meeting on High Power Diode Lasers & Systems will be held as part of the Enlighten Conference, October 14th & 15th August 4th, 2015

Atomic view of microtubules: Berkeley Lab researchers achieve record 3.5 angstroms resolution and visualize action of a major microtubule-regulating protein August 4th, 2015

World's quietest gas lets physicists hear faint quantum effects August 4th, 2015


Smart hydrogel coating creates 'stick-slip' control of capillary action July 27th, 2015

Miniature Technology, Large-Scale Impact: Winner of the 2015 Lindros Award for translational medicine, Kjeld Janssen is pushing the boundaries of the emerging lab-on-a-chip technology July 7th, 2015

Lehigh University researchers unveil engineering innovations at TechConnect 2015: TechConnect is the world's largest accelerator for industry-vetted emerging-technologies ready for commercialization June 11th, 2015

How to cut a vortex into slices: A group of physicists, lead by Olga Vinogradova, professor at the Lomonosov Moscow State University, came up with a way to stir up a liquid in the microchannel June 3rd, 2015


Artificial blood vessels become resistant to thrombosis August 4th, 2015

Engineering a better 'Do: Purdue researchers are learning how August 4th, 2015

Proving nanoparticles in sunscreen products August 4th, 2015

Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015

Patents/IP/Tech Transfer/Licensing

Quantum networks: Back and forth are not equal distances! July 28th, 2015

Reshaping the solar spectrum to turn light to electricity: UC Riverside researchers find a way to use the infrared region of the sun's spectrum to make solar cells more efficient July 27th, 2015

Smarter window materials can control light and energy July 22nd, 2015

Magnetic nanoparticles could be key to effective immunotherapy: New method moves promising strategy closer to clinical use July 15th, 2015

Financial Reports

Industrial Nanotech, Inc. Provides Update on PCAOB Audited Financials July 27th, 2015

Nanometrics to Announce Second Quarter Financial Results on July 23, 2015 July 2nd, 2015

Aspen Aerogels to Webcast 2015 Annual Meeting of Stockholders June 11th, 2015

Industrial Nanotech, Inc. Provides Update June 8th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project